Showing 81-90 of 254 results for "".
Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Targeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesWhy Assessing Vitiligo Activity is Critical for Limiting Spread
https://practicaldermatology.com/conferences/maui-derm-2024/why-assessing-vitiligo-activity-is-critical-for-limiting-spread/20248/Chief Medical Editor Neal Bhatia, MD talks with “Mr. Vitiligo Himself,” John E. Harris, MD, PhD about the importance of determining whether vitiligo patients are active or stable in order to “shut off” spreading as soon as possible.An Exciting Year in Dermatology
https://practicaldermatology.com/topics/psoriasis/an-exciting-year-in-dermatology/19929/From new topicals to novel systemic agents, several treatments may be coming to the market in the next two years, while existing therapies may see label expansions. Bruce Strober, MD, PhD offers a look at new MOAs and the evidence for their use.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Dr. Tsao, Dr. Friedlander Recap Biggest Developments for Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-tsao-dr-friedlander-recap-biggest-developments-for-maui-derm/32913/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, used a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Enhancing Your Procedures with Chemical Peels & Nutraceuticals
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/enhancing-your-procedures-with-chemical-peels-nutraceuticals/20274/Do chemical peels and nutraceuticals have a place in today's aesthetic practice? Yes, say Vivian Bucay, MD and Erin Gilbert, MD, PhD, speaking at Cosmetic Surgery Forum 2016 in Las Vegas. Get their pearls for successful integration. Get more info on Cosmetic Surgery Forum.Dr. Anderson on New Tech That ‘Could be Revolutionary’ at Maui Derm
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/dr-anderson-on-new-tech-that-could-be-revolutionary-at-maui-derm/32921/In-vivo microscopy that will change how dermatologists practice and potentially revolutionary drug delivery systems were among the technologies highlighted by R. Rox Anderson, MD, PhD, during “Innovation in Dermatology 2025: A Look Into the Future of Dermatology” at the Maui Derm Hawaii 2025 meetingWhat's the Best Approach to Lichen Planus?
https://practicaldermatology.com/topics/general-topics/what-s-the-best-approach-to-lichen-planus/18286/Lichen planus doesn't garner much attention in therapeutic discussions, perhaps because it is so challenging to treat. Kevin Wang, MD, PhD talks to host Adam Friedman, MD about the challenges of managing the disease and his approach to patient care.